UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 8, 2009
Date of Report (Date of earliest event reported)
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-14471
|
|
52-1574808 |
(State of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number) |
7720 North Dobson Road
Scottsdale, Arizona 85256
(Address of principal executive offices) (Zip Code)
(602) 808-8800
(Registrants telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events.
On May 8, 2009, Medicis Pharmaceutical Corporation (the Company) received a Paragraph IV
Patent Certification from Glenmark Generics Inc., USA (Glenmark) advising that Glenmark has filed
an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for
a generic version of VANOS®. Glenmark has not advised the Company as to the timing or status of
the FDAs review of its filing, or whether it has complied with FDA requirements for proving
bioequivalence. Glenmarks Paragraph IV Certification alleges that the Companys U.S. Patent No.
6,765,001 (the 001 Patent) and U.S. Patent No. 7,220,424 (the 424 Patent) will not be
infringed by Glenmarks manufacture, use or sale of the product for which the ANDA was submitted.
The expiration date for the 001 Patent is 2021, and the expiration date for the 424 Patent is
2023. The Company is evaluating the details of Glenmarks certification letter and considering its
options.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
Date: May 14, 2009 |
By: |
/s/ Jason D. Hanson
|
|
|
|
Jason D. Hanson |
|
|
|
Executive Vice President, General Counsel and Corporate Secretary |
|
|